Interferon for chronic hepatitis C
54 results
1 - 54
Ribavirin plus interferon versus interferon for chronic hepatitis C- Ribavirin with or without alpha interferon for chronic hepatitis C
- Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C
- Interferon for interferon naive patients with chronic hepatitis C: Cochrane systematic review
Effect of interferon-alpha on ALT in patients with chronic C or chronic non-A non-B hepatitis - Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C
- Ribavirin monotherapy for chronic hepatitis C
- Interferon for acute hepatitis C
- Glucocorticosteroids for viral hepatitis C
- Nitazoxanide for chronic hepatitis C
- Aminoadamantanes versus other antiviral drugs for chronic hepatitis C
- Aminoadamantanes for chronic hepatitis C
- Medicinal herbs for hepatitis C virus infection
Silymarin (milk thistle) does not improve disease markers for chronic HCV infection- Bile acids for viral hepatitis
- Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus
- Pharmacological interventions for acute hepatitis C infection
- Antiviral interventions for liver transplant patients with recurrent graft infection due to hepatitis C virus
- Interventions for dialysis patients with hepatitis C virus (HCV) infection
- Treatment for hepatitis C virus‐associated mixed cryoglobulinaemia
- Direct‐acting antivirals for chronic hepatitis C
- Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver transplantation: Cochrane systematic review
- Viral hepatitis
- Radix Sophorae flavescentis versus other drugs or herbs for chronic hepatitis B
- Telaprevir added to standard therapy improves SVR in hepatitis C genotype 1
- Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C
- Pharmacological interventions for acute hepatitis B infection
- Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow‐responder adult patients